| |
|
|
|
Xtalks, Online
2025-04-17
In this webinar, the expert speakers will explore advanced conjugation technologies such as antibody-drug conjugates (ADCs), antibody-RNA-conjugates (ARCs), siRNA/oligos and antibody-peptide conjugates, as well as discuss the best bioanalytical support strategies for these therapies.
Bioanalysis for support of next-generation ADCs and ARCs have exploded recently due to the efficacy and safety that these therapies offer for immuno-oncology, rare diseases, vaccines and potentially many other diseases.
ADCs tend to consist of a toxic small molecule payload attached via a linker to an antibody. The application of these drugs had mainly been in oncology where their mode of action is for the antibody to attach at the desired target site with subsequent release of the small molecule to combat tumor cells. Recently, we have seen a much wider application or use of “ADCs” to other modalities such as antibody-peptide conjugates, ARCs or even other more complicated multi-functional entities.
Having a therapeutic entity with multiple distinct components means that we need to have analytical methodologies for various components. Traditionally, LC-MS/MS has mainly been applied to the quantitation of the small molecule payload or the linker moiety. Ligand-binding assays had been successful for quantitation of the intact ADC or the antibody portion.
The expert speakers will discuss the latest and greatest conjugation technologies (ADCs, ARCs/siRNA/Oligo’s, Antibody peptide conjugates) and how best to support them bioanalytically. Those attending will specifically have the benefit of learning which PK methods are required for bioanalysis of conjugated drugs, various platforms used for PK methods, strategies for selection of the platform to be used for PK methods and PK case studies of conjugated drugs.
Additionally, this webinar will discuss immunogenicity strategies and case studies for support of conjugated drugs. Attendees will also learn what critical reagents are needed/recommended for support of conjugated drugs, challenges with multiplexing PK assays and regulatory expectations. Register for this webinar to learn how best to address these challenges.
Keywords: Pharmacokinetics, Drug Development, CRO, Biotherapeutics, Immunogenicity, Analytical Testing, Antibody-Drug Conjugate, Bioanalytical Testing, PK, ADCs, ARCs, siRNA
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Dominic Warrino, PhD, Senior Director of Scientific Services, KCAS Bio
Dawn Dufield, PhD, Scientific Officer, Mass Spectrometry, KCAS Bio
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2025-04-17
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|